TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02104115

Intervention type: OTHER
Group type: OTHER
Intervention: MRI scanners

Intervention type: OTHER
Group type: OTHER
Intervention: MRI scanners

Intervention type: OTHER
Group type: OTHER
Intervention: MRI scanners

Intervention type: OTHER
Group type: OTHER
Intervention: VAS Symptom scores

Intervention type: OTHER
Group type: OTHER
Intervention: VAS Symptom scores

Intervention type: OTHER
Group type: OTHER
Intervention: VAS Symptom scores
Study: NCT03148665

Intervention type: DEVICE
Intervention: OncAlert
Description: A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients

Intervention type: DEVICE
Intervention: OncAlert
Description: A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
Study: NCT01128179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate
Description: 1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo chewable tablets administered 3 times a day for 12 weeks
Study: NCT00520897

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir (MK0518)
Description: 400mg BID; 48 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400mg QD

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukopheresis
Description: pack of cells as per protocol

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Leukopheresis
Description: pack of cells as per protocol

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sigmoid Biopsy
Description: gut samples as per protocol
Study: NCT02754583

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.

Intervention type: DRUG
Group type: OTHER
Intervention: Tetracycline
Description: Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetracycline
Description: Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: The control group will receive no intervention during the trial. They will be enrolled in mass antibiotic treatment at the conclusion of the trial.
Study: NCT00997399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: panobinostat (LBH589)
Study: NCT02611141

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane
Description: To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack \& Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~1. Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~2. If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane
Description: To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack \& Lehane .~This score will be assessed at least 2 minutes after muscle relaxation:~1. Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):~2. If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.~Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used.
Study: NCT00702455

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Directed (weight loss maintenance)
Description: Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
Study: NCT01138605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Liquid formulation, 80 mg/ml, taken in combination with Darunavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 400 mg tablet, intake of 2 tablets once daily in combination with ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Liquid formulation, 80 mg/ml, taken in combination with Darunavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
Study: NCT00320619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epsilon-Aminocaproic Acid (EACA)
Description: Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
Study: NCT02498340

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: non- fava beans
Description: Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
Study: NCT01063699

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Kasai operation
Description: the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
Study: NCT04184752

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.

Intervention type: DIAGNOSTIC_TEST
Intervention: Urodynamic study
Description: The urodynamic assessment included uroflowmetry, filling cystometry with 35°C distilled water at a rate of 60 mL/sec, a pressure flow study, and a stress urethral pressure profile with patient in sitting position \[14\]. A 20-minute pad test for each woman was also performed \[15, 16\]. Multichannel urodynamic equipment (Life-Tech, Houston, TX, USA) with computer analysis and Urovision (Urolab Janus System V, Houston) was used. All terminology conformed to the standards recommended by the ICS \[3\]. All procedures were performed by an experienced technician, and the data were interpreted by a single observer to avoid interobserver variability.
Study: NCT01083615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: custirsen sodium
Description: An antisense oligonucleotide that blocks production of clusterin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: isotonic, 0.9% sodium chloride
Description: Placebo for custirsen sodium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cabazitaxel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cabazitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisone
Study: NCT00902473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: 25mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: 25mg tablets
Study: NCT04411472

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant human alkaline phosphatase
Description: patients with SA-AKI are randomly assigned in a 1:1 ratio to either placebo or 1.6 mg/kg recAP.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03331939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no stimulation
Description: Vagal nerve stimulator will be set to no stimulation

Intervention type: OTHER
Group type: OTHER
Intervention: beta (25-30 Hz)
Description: Vagal nerve stimulator will be set to beta (25-30 Hz)

Intervention type: OTHER
Group type: OTHER
Intervention: Theta (5 Hz)
Description: Vagal nerve stimulator will be set to beta (5 Hz)
Study: NCT00702455

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guided (weight loss maintenance)
Description: Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
Study: NCT01016314

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aspen Spinous Process System
Description: Aspen Spinous Process System is an interspinous process fixation device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pedicle Screw Fixation
Description: Pedicle Screws are used for the fixation of the spine
Study: NCT01968577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 40 mg before percutaneous coronary intervention
Study: NCT04172961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanomicellular cyclosporine 0.09%
Description: topical ophthalmic drop prior to elective surgery for eligible patients

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lifitegrast
Description: topical ophthalmic drop prior to elective surgery for eligible patients
Study: NCT04581343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab injection; spartalizumab, nab-paclitaxel, gemcitabine
Description: Canakinumab 250 mg s.c. injection; Spartalizumab 400 mg IV infusion, nab-paclitaxel 125 mg/m2 IV infusion, gemcitabine 1000 mg/m2 IV infusion
Study: NCT00299013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLAL-PRED®
Description: COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLAL-PRED®
Description: COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
Study: NCT03622177

Intervention type: PROCEDURE
Intervention: biopsie
Description: Additional colorectal mucosal biopsies during rectoscopy or colonoscopy

Intervention type: PROCEDURE
Intervention: biopsie
Description: Additional colorectal mucosal biopsies during rectoscopy or colonoscopy

Intervention type: PROCEDURE
Intervention: biopsie
Description: Additional colorectal mucosal biopsies during rectoscopy or colonoscopy

Intervention type: BIOLOGICAL
Intervention: blood drawn
Description: Additional blood drawn by venepuncture
Study: NCT00520897

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Sigmoid Biopsy
Description: gut samples as per protocol
Study: NCT01969500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Study: NCT02639338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL/VOX
Description: 400/100/100 mg FDC tablet administered orally once daily with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF/VEL
Description: 400/100 mg FDC tablet administered orally once daily without regard to food
Study: NCT02428920

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Groups
Description: The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
Study: NCT01893359

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riboflavin ophthalmic solution, 0% dextran

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: riboflavin ophthalmic solution, 0% dextran

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Laser-assisted in situ keratomileusis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser-assisted in situ keratomileusis
Study: NCT03838497

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Description: Prevenar13 for both arms

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar13
Description: Prevenar13 for both arms
Study: NCT04271917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Use of cannabidiol as an alternative to standard of care treatment of acute pain.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cannabidiol
Description: Use of cannabidiol as an alternative to standard of care treatment of acute pain.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Inactive placebo oil to imitate CBD oil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen 500mg and ibuprofen 200mg combo
Description: standard of care
Study: NCT02303821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Study: NCT01893359

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser-assisted in situ keratomileusis
Study: NCT01341626

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Foster Care (TFCO)
Description: Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group Care
Description: Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
Study: NCT03167489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Plus Emotional Regulation
Description: Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
Study: NCT01634529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V158866
Description: Single ascending oral doses of V158866 and Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: V158866
Description: Multiple ascending oral doses of V158866 and Placebo
Study: NCT01367392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: biopsy or ablation
Description: biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
Study: NCT02570243

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of Unfractionated Heparin
Description: Unfractionated Heparin 100IU/Kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard dose of Unfractionated heparin
Description: Unfractionated heparin 50IU/Kg
Study: NCT03541187

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: German cockroach allergenic extract
Description: Active ingredient: a non-standardized allergen derived from the extraction and purification of proteins from German cockroach (Blattella germanica). Non-standardized glycerinated German cockroach allergenic extract is approved in the United States for diagnostic skin testing and immunotherapy by subcutaneous injection (U.S. License 467).

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for German cockroach allergenic extract
Description: Commercially- labeled licensed product, sterile diluent for allergenic extract (50% glycerinated), sodium bicarbonate (0.091%) sodium chloride (0.166%).
Study: NCT00961792

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol
Description: Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Beverage containing 0.0 g/kg alcohol to act as placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake